The trial also assessed the pharmacodynamics of oral doses of CDX-7108 in ten exocrine pancreatic insufficiency patients. Credit: Herney Gómez from Pixabay.

Codexis and Nestlé Health Science have reported interim results from a Phase I clinical trial of CDX-7108 for exocrine pancreatic insufficiency (EPI).

The Phase I trial has been designed for assessing the tolerability, pharmacokinetics (PK), and safety of escalating oral CDX-7108 doses in 48 healthy adult participants.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is also evaluating the pharmacodynamics of oral CDX-7108 doses as part of a proof-of-concept study in ten EPI patients.

Codexis stated that the interim analysis included five participants and studied lipid absorption as measured by 13CO2 excretion.

There were no serious adverse events (SAE) and no safety issues observed in the trial.

See Also:

Additionally, no treatment discontinuations were observed in both the single ascending dose (SAD) and multiple ascending dose (MAD) healthy participant groups.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the proof-of-concept part of the trial, every EPI patient had improved lipid absorption when CDX-7108 was given, compared to a placebo.

A significant increase in the cumulative excretion rate of 13CO₂ was observed for CDX-7108, after combining the data from each participant.

Codexis CEO and president Stephen Dilly said: “Preliminary data from an interim analysis of our Phase 1 study proof-of-concept arm has shown indication of improved lipid absorption when patients were administered CDX-7108 versus a placebo.

“These encouraging data support a path forward, further developing CDX-7108 with Nestlé Health Science. We aim for the potential initiation of a Phase II study in early 2024.”

By the end of this year, Codexis and Nestlé Health Science intend to file an Investigational New Drug (IND) application for the Phase II trial, which is anticipated to be conducted over nearly 12 months.

Topline data from the Phase II trial is expected in 2025.